Press release
Achalasia Treatment Market Poised to Expand at a Robust Pace over 2018 to 2028
Across the globe, approximately 5% of the global population is suffering from a rare disorder, which makes the treatment of rare disorders a deliberating concern. Achalasia is a rare disorder of the oesophagus that is generally characterized by the incomplete relaxation of the lower oesophageal sphincter in response to swallowing. The symptoms of achalasia include chest pain, weight loss, heartburn, regurgitation, nocturnal coughing, dysphagia and postprandial aspiration, among others. Dysphagia is the most common symptom in patients suffering from achalasia. The causes of achalasia are still unknown. Achalasia is associated with abnormalities of oesophageal peristalsis. Achalasia treatment involves the removal of obstructions caused because the lower oesophageal sphincter muscle fails to relax. Drugs such as isosorbide or nifedipine can provide some relief to patients suffering from achalasia. It is estimated that approximately 70% of achalasia cases are more effectively treated by the enlargement of the lower oesophageal sphincter muscle through a procedure known as pneumatic balloon dilation. Achalasia generally affects adults aged between 25 and 60 years. However, it is likely to occur at any age, including childhood. The symptoms of achalasia appear gradually. People suffering from achalasia are expected to be at the risk of developing oesophageal cancer.Request for Brochure @ https://www.factmr.com/connectus/sample?flag=B&rep_id=992
Achalasia Treatment Market: Drivers and Restraints
Increasing research grants and R&D expenditure form governments is driving the growth of the global achalasia treatment market. Rising government support is encouraging the development of treatment options for achalasia and are expected to change the landscape of achalasia treatment over the forecast period (2018-2028). Furthermore, the presence of a small number of affected people is likely to put a severe strain on the healthcare system. Rare disorders are supported by well-organized patient advocacy organizations such as National Organization for Rare Disorders (NORD). However, inadequate treatment information about achalasia among healthcare providers is expected to restrain the global achalasia treatment market. In addition, awareness and understanding of rare disorders such as achalasia are often low and several patients are struggling to find adequate information about it. These factors are also expected to hamper the growth of the global achalasia treatment market.
Visit For TOC @ https://www.factmr.com/connectus/sample?flag=T&rep_id=992
Achalasia Treatment Market: Segmentation
The global achalasia treatment market has been segmented on the basis of treatment, end user and geography.
Based on treatment, the global achalasia treatment market is segmented as:
Non-Surgical Treatment
Botulinum toxin type A
Pneumatic dilation
Others
Surgical Treatment
Peroral Endoscopic Myotomy (POEM)
Heller Myotomy
Others
Based on End User, the global achalasia treatment market is segmented as:
Hospitals
Specialty Clinics
Research Institutes
Achalasia Treatment Market: Overview
Over the forecast period, achalasia treatment market is expected to witness moderate growth. Approximately 85-90% of achalasia cases can be treated with surgical procedures. During surgical procedures, the muscle fibres in the lower oesophageal sphincter are cut. Among surgical treatment types, the Heller Myotomy segment is expected to lead in the global achalasia treatment market over the forecast period. The hospitals end-user segment is expected to contribute to the maximum market share in the global achalasia treatment market. Achalasia treatment for patients majorly focuses on the improvement of symptoms.
Achalasia Treatment Market: Regional Outlook
Geographically, the global achalasia treatment market is segmented into North America, Latin America, Europe, Asia-Pacific excluding Japan (APEJ), Japan and the Middle East and Africa (MEA). North America is expected to continue to dominate the global achalasia treatment market owing to the presence of prominent key players and favourable reimbursement scenario in the region. The Asia Pacific achalasia treatment market is expected to grow at a maximum CAGR over the forecast period due to the entry of new players in the region and increasing awareness about achalasia treatment. The Middle East & Africa and Latin America regions are expected to hold a minimum market share in the global achalasia treatment market owing to lack of strategies for access to treatments for achalasia.
Achalasia Treatment Market: Key Players
Some of the key players operating in the global achalasia treatment market are Allergan plc; Ipsen Biopharmaceuticals, Inc.; Nestlé Skin Health (Galderma S.A.); Merz Pharma; Aesculap, Inc. and Silex Medical, LLC.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
The report covers exhaustive analysis on:
Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Technology
Value Chain
Regional analysis includes
North America (U.S., Canada)
Latin America (Mexico, Brazil)
Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)
Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
Asia Pacific Excluding Japan (China, India, Australia & New Zealand)
Japan
Middle East and Africa (GCC, S. Africa, Rest Of MEA)
Report Highlights:
Detailed overview of parent market
Changing market dynamics in the industry
In-depth market segmentation
Historical, current and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint.
About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.
Contact Us
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Follow us in Linkedin: https://www.linkedin.com/company/factmr/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Achalasia Treatment Market Poised to Expand at a Robust Pace over 2018 to 2028 here
News-ID: 1133801 • Views: …
More Releases from Fact.MR

Bioinformatics Market is Growing at a CAGR of 13.4% by 2034 | Fact.MR Report
The latest report on the Bioinformatics Market, projecting robust growth driven by the increasing demand for genomic research, advancements in artificial intelligence (AI), and the rising adoption of precision medicine. Valued at USD 14.29 billion in 2024, the global market is forecast to expand at a compound annual growth rate (CAGR) of 13.4%, reaching USD 50.25 billion by 2034. This significant growth underscores the critical role of bioinformatics in decoding…

Residential Robotic Vacuum Cleaner Market to Reach USD 11.6 Billion by 2033 | Ke …
Fact.MR today released its latest report on the Residential Robotic Vacuum Cleaner Market, projecting robust growth driven by increasing demand for automation, busy lifestyles, and advancements in smart home technologies. Valued at USD 3.0 billion in 2023, the global market is forecast to expand at a compound annual growth rate (CAGR) of 14.4%, reaching USD 11.6 billion by 2033. This significant growth highlights the rising adoption of robotic vacuum cleaners…

Brain-Computer Interface Market is Estimated to Reach USD 6.5 Billion by 2033
The global brain-computer interface (BCI) market was valued at USD 1.6 billion in 2022 and is projected to reach USD 6.5 billion by 2033, growing at a compound annual growth rate (CAGR) of 13.6% from 2023 to 2033. This expansion reflects the increasing adoption of BCI technologies in medical applications, driven by advancements in neuroscience, AI, and sensor technologies. BCIs enable direct communication between the brain and external devices, offering…

Orally Disintegrating Tablet Market is Projected to Reach USD 72.68 Billion by 2 …
The global orally disintegrating tablet (ODT) market is valued at USD 24.45 billion in 2024 and is forecasted to expand at a compound annual growth rate (CAGR) of 11.5%, reaching USD 72.68 billion by 2034. This robust growth is driven by the increasing demand for patient-friendly dosage forms, particularly among the elderly, pediatric, and dysphagic populations, who benefit from ODTs' ease of administration without water and rapid dissolution. ODTs enhance…
More Releases for Achalasia
Esophageal Achalasia Market to Reach USD 720 Million by 2034
Esophageal achalasia is a rare, chronic motility disorder characterized by the inability of the lower esophageal sphincter (LES) to relax and by the absence of normal esophageal peristalsis. This condition results in difficulty swallowing (dysphagia), regurgitation, chest pain, and weight loss. Though uncommon, achalasia has significant clinical consequences, and without proper treatment it can progress to severe esophageal dilation or even esophageal cancer in some cases.
Download Full PDF Sample Copy…
Achalasia Treatment Market Size And Global Industry Forecast 2034
"The achalasia treatment market is valued at approximately $1.2 billion in 2024, driven by rising incidences of esophageal disorders and advancements in therapeutic techniques. The market is projected to grow significantly, reaching an estimated $2.3 billion by 2034, reflecting a robust CAGR of 6.8% during the forecast period of 2025 to 2034. "
Exactitude Consultancy., Ltd. released a research report titled "Achalasia Treatment Market". This report covers the global Achalasia Treatment…
Achalasia Treatment Market to Witness Growth Acceleration By 2028
Across the globe, approximately 5% of the global population is suffering from a rare disorder, which makes the treatment of rare disorders a deliberating concern. Achalasia is a rare disorder of the oesophagus that is generally characterized by the incomplete relaxation of the lower oesophageal sphincter in response to swallowing. The symptoms of achalasia include chest pain, weight loss, heartburn, regurgitation, nocturnal coughing, dysphagia and postprandial aspiration, among others. Dysphagia…
Achalasia Treatment Market Expansion Projected to Gain an Uptick During 2018 to …
Across the globe, approximately 5% of the global population is suffering from a rare disorder, which makes the treatment of rare disorders a deliberating concern. Achalasia is a rare disorder of the oesophagus that is generally characterized by the incomplete relaxation of the lower oesophageal sphincter in response to swallowing. The symptoms of achalasia include chest pain, weight loss, heartburn, regurgitation, nocturnal coughing, dysphagia and postprandial aspiration, among others. Dysphagia…
Achalasia Treatment Market to receive over whelming hike in Revenues by 2018 to …
Across the globe, approximately 5% of the global population is suffering from a rare disorder, which makes the treatment of rare disorders a deliberating concern. Achalasia is a rare disorder of the oesophagus that is generally characterized by the incomplete relaxation of the lower oesophageal sphincter in response to swallowing. The symptoms of achalasia include chest pain, weight loss, heartburn, regurgitation, nocturnal coughing, dysphagia and postprandial aspiration, among others. Dysphagia…
Global Achalasia Treatment Market: A comprehensive study by Key Players: Achalas …
Across the globe, approximately 5% of the global population is suffering from a rare disorder, which makes the treatment of rare disorders a deliberating concern. Achalasia is a rare disorder of the oesophagus that is generally characterized by the incomplete relaxation of the lower oesophageal sphincter in response to swallowing. The symptoms of achalasia include chest pain, weight loss, heartburn, regurgitation, nocturnal coughing, dysphagia and postprandial aspiration, among others. Dysphagia…